Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Inivata Ltd Company Overview 5
Inivata Ltd Company Snapshot 5
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Inivata Ltd – Pipeline Analysis Overview 7
Inivata Ltd – Key Facts 7
Inivata Ltd – Major Products and Services 8
Inivata Ltd Pipeline Products by Development Stage 9
Inivata Ltd Ongoing Clinical Trials by Trial Status 10
Inivata Ltd Pipeline Products Overview 12
InVision ctDNA Assay – EGFR-Mutant NSCLC 12
InVision ctDNA Assay – EGFR-Mutant NSCLC Product Overview 12
InVision ctDNA Assay – Metastatic Breast Cancer 13
InVision ctDNA Assay – Metastatic Breast Cancer Product Overview 13
InVision ctDNA Assay – NSCLC 14
InVision ctDNA Assay – NSCLC Product Overview 14
InVision ctDNA Assay – NSCLC Clinical Trial 15
InVision ctDNA Assay – Pancreatic Cancer 16
InVision ctDNA Assay – Pancreatic Cancer Product Overview 16
InVision ctDNA Assay – Stage III/IV NSCLC 17
InVision ctDNA Assay – Stage III/IV NSCLC Product Overview 17
InVision First 18
InVision First Product Overview 18
InVision First Clinical Trial 19
Inivata Ltd – Key Competitors 20
Inivata Ltd – Key Employees 21
Inivata Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Inivata Ltd, Recent Developments 23
Jun 01, 2018: Addario Lung Cancer Medical Institute Collaborates with Washington University on ctDNA Analysis in Early Stage Lung Cancer Study 23
May 08, 2018: Michael Stocum to step down as Inivata CEO 23
Apr 11, 2018: Presentation of New Data on Inivata’s Industry-Leading Liquid Biopsy Platform at AACR 2018 Annual Meeting 24
Mar 19, 2018: Inivata Publishes Results of Analytical Validation for InVisionFirst-Lung ctDNA Liquid Biopsy 24
Mar 15, 2018: Inivata Announces Collaboration with MedStar Health to Utilize Liquid Biopsy to Advance Precision Cancer Genomics 25
Oct 26, 2017: Inivata Announces World-Leading SAB 25
Oct 17, 2017: Inivata Highlights New Clinical Data on InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 26
Oct 17, 2017: Inivata Highlights New Clinical Data on InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 27
Oct 13, 2017: Inivata Collaborates with Genomics England to Assess Samples and Explore Potential of Liquid Biopsy to Improve Cancer Management and Patient Outcomes 28
Sep 27, 2017: Addario Lung Cancer Medical Research Institute and Inivata Announce Major Study of ctDNA Analysis in Early Stage Lung Cancer 28
Appendix 29
Methodology 29
About GlobalData 32
Contact Us 32
Disclaimer 32
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Inivata Ltd Pipeline Products by Equipment Type 6
Inivata Ltd Pipeline Products by Indication 6
Inivata Ltd Ongoing Clinical Trials by Trial Status 6
Inivata Ltd, Key Facts 7
Inivata Ltd, Major Products and Services 8
Inivata Ltd Number of Pipeline Products by Development Stage 9
Inivata Ltd Pipeline Products Summary by Development Stage 9
Inivata Ltd Ongoing Clinical Trials by Trial Status 10
Inivata Ltd Ongoing Clinical Trials Summary 11
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Status 12
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Description 12
InVision ctDNA Assay - Metastatic Breast Cancer - Product Status 13
InVision ctDNA Assay - Metastatic Breast Cancer - Product Description 13
InVision ctDNA Assay - NSCLC - Product Status 14
InVision ctDNA Assay - NSCLC - Product Description 14
InVision ctDNA Assay - NSCLC - Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation: LIBERTI 15
InVision ctDNA Assay - Pancreatic Cancer - Product Status 16
InVision ctDNA Assay - Pancreatic Cancer - Product Description 16
InVision ctDNA Assay - Stage III/IV NSCLC - Product Status 17
InVision ctDNA Assay - Stage III/IV NSCLC - Product Description 17
InVision First - Product Status 18
InVision First - Product Description 18
InVision First - Analytical Validation of a Next Generation Sequencing Liquid Biopsy Assay for High Sensitivity Broad Molecular Profiling 19
InVision First - Evaluation of Liquid Biopsies for Molecular Profiling in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) in the Relapse Treatment Setting 19
InVision First - Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared with Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients with Advanced Non-small Cell Lung Cancer 19
Inivata Ltd, Key Employees 21
Inivata Ltd, Subsidiaries 22
Glossary 31
List of Figures
Inivata Ltd Pipeline Products by Equipment Type 6
Inivata Ltd Pipeline Products by Development Stage 9
Inivata Ltd Ongoing Clinical Trials by Trial Status 10